Zambia AIDS Malignancies Diagnosis and Pathogenesis Program Supplement

摘要 赞比亚艾滋病恶性肿瘤诊断和发病机制项目（ZAMDAPP）的建立将 支持美国与赞比亚之间的合作，以开发强大的癌症研究基础设施 赞比亚癌症疾病医院 (CDH) 和大学教学医院 (UTH)，最初的重点是 卡波西肉瘤 (KS) 和眼表鳞状细胞瘤 (OSSN) – 两种最常见的肿瘤 该国与艾滋病毒/艾滋病相关的恶性肿瘤。 ZAMDAPP将首次提供一种机制： 由赞比亚科学家领导的R01型研究项目通过福格蒂国际艾滋病培训 国际研究和培训计划（AITRP，D43TW001429）和艾滋病恶性肿瘤培训和 研究计划（AMTRP，D43TW010354）可在对癌症研究至关重要的三个领域进行 - 病毒学、生物统计学和流行病学以及癌症诊断。领导研究的赞比亚人员 项目将受益于美国合作伙伴的指导和许多研究核心设施的支持。 ZAMDAPP 将利用 CDH 和 UTH 的临床护理和治疗优势；分子病毒的优势 内布拉斯加大学林肯分校的肿瘤学研究和癌症基因组学；和病理学方面的优势， 内布拉斯加大学医学中心的流行病学和生物统计学，同时扩展了已经开展的工作 通过 AITRP 和 AMTRP 完成，为学员追求高级课程提供支持 度。除了提供研究经费外，ZAMDAPP还将在以下领域提供多样化的培训活动： 美国和赞比亚将吸引下一代赞比亚癌症研究人员，增加当地 专业知识，加强技术转让。此次合作将促进交流，构建 进行高质量和可持续的癌症研究所需的技术和人员基础设施 赞比亚急需。将实现三个具体目标：1）发展癌症研究 通过建立和加强两个研究核心设施，UTH 和 CDH 的基础设施； 2） 为前福格蒂培训研究员提供机会，领导这两个领域的假设驱动研究项目 在美国合作伙伴和 核心设施； 3) 通过 a) 国内开发下一代赞比亚癌症研究人员的渠道 研讨会，b) 试点项目资助，以及 c) 短期美国技术培训。 ZAMDAPP 将建立在 由 PI 和领导层领导的正在进行的 Fogarty 和国家癌症研究所培训计划取得成功 撒哈拉以南非洲团队；实施跨学科研究和培训计划 赞比亚和美国研究人员配对的培训课程和国内研究项目 进行假设驱动的研究项目的机会；并以赞比亚为动力并从广泛的 本地支持。因此，ZAMDAPP 成功实现其目标的潜力很大。

ABSTRACT The establishment of the Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP) will support the U.S.-Zambia collaborations necessary to develop a robust cancer research infrastructure at Zambia’s Cancer Diseases Hospital (CDH) and University Teaching Hospital (UTH), with an initial focus on Kaposi’s sarcoma (KS) and ocular surface squamous neoplasia (OSSN) – two of the most common occurring HIV/AIDS-associated malignancies in the country. ZAMDAPP will, for the first time, provide a mechanism by which R01-style research projects led by Zambian scientists trained through the Fogarty International AIDS International Research and Training Program (AITRP, D43TW001429) and AIDS Malignancies Training and Research Program (AMTRP, D43TW010354) may be conducted in three areas critical to cancer research – virology, biostatistics and epidemiology, and cancer diagnostics. The Zambian personnel leading the research projects will benefit from mentoring by U.S. partners and support by a number of research core facilities. ZAMDAPP will leverage strengths in clinical care and treatment at CDH and UTH; strengths in molecular viral oncology research and cancer genomics at the University of Nebraska-Lincoln; and strengths in pathology, epidemiology, and biostatistics at the University of Nebraska Medical Center, while extending the work that has been accomplished through AITRP and AMTRP, which provide support for trainees to pursue advanced degrees. In addition to providing research funding, ZAMDAPP will provide diverse training activities in the United States and Zambia to engage the next generation of Zambian cancer researchers, increase local expertise, and enhance the transfer of technology. The partnership will lead to exchanges that build the technical and personnel infrastructure necessary to perform the high-quality and sustainable cancer research desperately needed in Zambia. Three specific aims will be accomplished: 1) develop the cancer research infrastructure at UTH and CDH through the establishment and enhancement two research core facilities; 2) provide an opportunity for former Fogarty trained fellows to lead hypothesis-driven research projects in the two more prevalent AIDS-associated malignancies, KS and OSSN, with the support of the U.S. partners and the core facilities; and 3) develop a pipeline of next generation Zambian cancer researchers through a) in-country workshops, b) pilot project funding, and c) short-term U.S. technical training. ZAMDAPP will build on successful ongoing Fogarty and National Cancer Institute training programs led by the PI and the leadership team in sub-Saharan Africa; implement a cross-disciplinary research and training program with different training tracks and in-country research projects that pair Zambian and U.S. researchers along with opportunities to conduct hypothesis-driven research projects; and be Zambian driven and benefit from broad local support. Thus, there is strong potential for ZAMDAPP to success in reaching its goal.